Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I randomized, dose-escalation, double-blind, placebo-controlled single ascending dose study of NRL-1049 in Patients with Cerebral Cavernous Malformations

Next Previous
X
Search
Trial Profile

Phase I randomized, dose-escalation, double-blind, placebo-controlled single ascending dose study of NRL-1049 in Patients with Cerebral Cavernous Malformations

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NRL 1049 (Primary)
  • Indications Central nervous system cavernous haemangioma
  • Focus Adverse reactions; First in man
  • Sponsors Neurelis

    • Most Recent Events

    • 24 Mar 2023 According to Neurelis media release, investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) was accepted for NRL-1049 earlier this year.
    • 24 Mar 2023 Status changed from not yet recruiting to recruiting, according to a Neurelis media release.
    • 24 Mar 2023 According to Neurelis media release, first two cohorts dosed has been dosed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top